Clinical Trial

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2025 (before its estimated December 5, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase III clinical trial designed to evaluate the efficacy and safety of XZP-3287 in combination with Letrozole/Anastrozole versus placebo in combination with Letrozole/Anastrozole in patients with HR-positive and HER2-negative recurrent/metastatic breast cancer who have not received systemic anticancer therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-02-16; most recent amendment 2025-07-14.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-04-18
Trial Details
NCT Number NCT05257395
Lead Sponsor Xuanzhu Biopharmaceutical Co., Ltd.
Conditions Advanced Breast Cancer
Enrollment 397 participants
Start Date 2022-03-14
Primary Completion 2025-12-05 (estimated)
Study Completion 2030-09-05 (estimated)
Updated on ClinicalTrials.gov 2025-07-17